Pricing Log in Create free account
Friday 6 November 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

329.11 16.09 +5.14%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Charles River Laboratories International, Inc. 10-Q filed May 7, 2026

Fiscal Q1 2026 · Period ended Mar 28, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 16 added · 38 removed · 24 modified; 7 with only figures updated; 6 moved without change

  1. Modified · Global Market Environment

    We are continuing to see a cautious spending environment from our client base, principally within our DSA segment related to our global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structuresthe challenging demand environment experienced in the recent prior quarters has persisted. As we continue to navigate these challenges in the current macroeconomic environment, DSA backlog declined slightly toheld consistent at $1.81.9 billion as of September 27March 28, 2025 from $2.0 billion as of 2026 and December 2827, 20242025, respectively.